Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline

References

• Martinez-Castelao A, Navarro-Gonzalez JF, Górriz J., et al. The concept and the epidemiology of diabetic nephropathy have changed in recent years. J Clin Med. 2015;4(6):1207–1216. doi:10.3390/jcm4061207
   Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: challenges, Progress, and Possibilities. Clin J Am SocNephrol. 2017;12:2032–2045. doi:10.2215/CJN.11491116
   PubMed Web of Science ®Google Scholar
• Klessens CQF, Woutman TD, Veraar KAM, et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int. 2016;90:1–8. doi:10.1016/j.kint.2016.01.023
   Web of Science ®Google Scholar
• Skupien J, Warram JH, Smiles AM, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 2012;82:589–597. doi:10.1038/ki.2012.189
   PubMed Web of Science ®Google Scholar
• Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38(6):954–962. doi:10.2337/dc15-0184
   PubMed Web of Science ®Google Scholar
• Weldegiorgis M, de Zeeuw D, Li L, et al. Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy. Am J Kidney Dis. 2018;71:91–101. doi:10.1053/j.ajkd.2017.08.010
   PubMed Web of Science ®Google Scholar
• Ragot S, Saulnier PJ, Velho G, et al. Dynamic changes in renal function are associated with major cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2016;39:1259–1266. doi:10.2337/dc15-2607
   Web of Science ®Google Scholar
• Naimark DM, Grams ME, Matsushita K, et al. Past decline versus current eGFR and subsequent mortality risk. J Am SocNephrol. 2015;27:2456–2466.
   Web of Science ®Google Scholar
• Furuichi K, Shimizu M, Yamanouchi M, et al. Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy. BMJ Open Diab Res Care. 2020;8:e001157. doi:10.1136/bmjdrc-2019-001157
   Web of Science ®Google Scholar
• Pinsker JE, Shank T, Dassau E, et al. Comment on American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes-2015. Diabetes Care. 2015;38(Suppl.1):e174. doi:10.2337/dc15-0839
   Web of Science ®Google Scholar
• Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J AmSocNephrol. 2010;21:556–563.
   Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Li L, et al. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy. Ren Fail. 2018;40:243–251. doi:10.1080/0886022X.2018.1456453
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180. doi:10.1016/S0140-6736(11)60178-5
   PubMed Web of Science ®Google Scholar
• Krolewski AS, Skupien J, Rossing P, et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91:1300–1311. doi:10.1016/j.kint.2016.10.046
   PubMed Web of Science ®Google Scholar
• Clark WF, Macnab JJ, Sontrop JM, et al. Dipstick proteinuria as a screening strategy to identify rapid renal decline. J Am SocNephrol. 2011;22:1729–1736.
   Web of Science ®Google Scholar
• Mise K, Hoshino J, Ueno T, et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab Res Rev. 2015;31:572–581. doi:10.1002/dmrr.2633
   Web of Science ®Google Scholar
• De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320. doi:10.1111/j.1523-1755.2004.00653.x
   PubMed Web of Science ®Google Scholar
• Abbate M, Zoja C, Remuzzi G. How Does Proteinuria Cause Progressive Renal Damage? J Am Soc Nephrol. 2006;17:2974–2984. doi:10.1681/ASN.2006040377
   PubMed Web of Science ®Google Scholar
• Zhao L, Ren H, Zhang J, et al. Diabetic retinopathy, classified using the lesion-aware deep learning system, predicts diabetic end-stage renal disease in Chinese patients. Endocrine Practice. 2020;26:429–443. doi:10.4158/EP-2019-0512
   PubMed Web of Science ®Google Scholar
• Galiero R, Pafundi PC, Nevola R, et al. The Importance of Telemedicine during COVID-19 Pandemic: a Focus on Diabetic Retinopathy. J Diabetes Res. 2020;14:9036847.
   Google Scholar
• Sasso FC, Pafundi PC, Gelso A, et al. for screening diabetic retinopathy: the NO BLIND Italian multicenter study. Diabetes Metab Res Rev. 2019;35(3):e3113. doi:10.1002/dmrr.3113
   Web of Science ®Google Scholar
• Parving H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. doi:10.1056/NEJMoa011489
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Mahaffey KW, Perkovic V. Canagliflozin and renal outcomes in diabetic nephropathy. Reply N Engl J Med. 2019;381:1089–1090.
   Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644–657. doi:10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:743–754. doi:10.1016/S2213-8587(21)00242-4
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao L, Zhang J, et al. Implications of a Family History of Diabetes and Rapid eGFR Decline in Patients With Type 2 Diabetes and Biopsy-Proven Diabetic Kidney Disease. Front Endocrinol (Lausanne). 2019;10:e00855. doi:10.3389/fendo.2019.00855
   Web of Science ®Google Scholar
• Li L, Zhang X, Li Z, et al. Renal pathological implications in type 2 diabetes mellitus patients with renal involvement. J Diabetes Complications. 2017;31:114–121. doi:10.1016/j.jdiacomp.2016.10.024
   PubMed Web of Science ®Google Scholar
• Mottl AK, Gasim A, Schober FP, et al. Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD. J Am SocNephrol. 2018;29:694–703.
   Web of Science ®Google Scholar
• Okada T, Nagao T, Matsumoto H, et al. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrology. 2012;17:68–75. doi:10.1111/j.1440-1797.2011.01525.x
   Web of Science ®Google Scholar